Patient specific case scenarios that unfold throughout the report, presented to 174 high-prescribing oncologists on ER/PR Positive HER2neu Negative Metastatic Breast Cancer for their open responses on clinical decisions, distributed and collected December 15, 2010 and January 10, 2011. Patient progression reveals decisions in treatment throughout patient stages, factors influencing their decisions, barriers to optimal care, and confidence in treatment.
Patient case highlights:
In treating an 85-year-old woman presenting with hip pain who was diagnosed with ER/PR positive HER2/neu negative metastatic breast cancer and who underwent a simple mastectomy, 9 of 10 oncologists would recommend xx….To treat her breast cancer, 5 in 10 oncologists would choose…
In a 60-year-old woman with diabetes, hypertension, renal insufficiency, and chronic obstructive pulmonary disease who found a lump in her breast and tests revealed metastatic lesions in ribs, spine, and femur initially treated with…
Data has been synthesized to show the highest reported responses, “other” responses, and direct quotes from the oncologists. This is the primary research for the oncology prescribing data that you are missing - directly from high-prescribing US oncologists on ER/PR Positive HER2neu Negative Metastatic Breast Cancer.
Treatment decisions for advanced stages of breast cancer are difficult to track as information quickly changes along with the introduction of new products that all have an impact oncologists’ choices. This report is part of a series of oncology reports that allow you to see what is actually happening at the patient level for different types of patients presenting with a wide range of issues in advanced stages of cancer.
This report allows you to:
Two patient specific case scenarios that unfold throughout the report, presented to high-prescribing oncologists on ER/PR HER2/neu Negative Metastatic Breast Cancer for their clinical decisions. In a survey including 174 oncologists’ responses, for specified patient with ER/PR positive HER2/neu negative metastatic breast cancer with comorbidities, 6 in 10 oncologists would….